Ethynylated Heterodinucleotide Cytostatic Drugs for a better Cancer Therapy

Our invention describes so called duplex drugs by using phosphodiester bounding as a linker between two nucleoside analogues. Their in vivo metabolism delivers a mixture of highly active antimetabolites. First experimental data demonstrate advantages of our duplex drugs compared to classical nucleoside analogues against some types of cancer cells.

Further Information: PDF

Eberhard Karls Universität Tübingen
Phone: +49 (7071) 29-72639

Contact
Dr. Rolf Hecker

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

New anti-cancer agent works without oxygen

Why tumors shrink but don’t disappear. “As tumors grow very quickly, consume a lot of oxygen and their vascular growth can’t necessarily keep pace, they often contain areas that are…

First blueprint of the human spliceosome revealed

Researchers detail the inner workings of the most complex and intricate molecular machine in human biology. Researchers at the Centre for Genomic Regulation (CRG) in Barcelona have created the first…

A paper-aluminum combo for strong, sustainable packaging

Takeout containers get your favorite noodles from the restaurant to your dining table (or couch) without incident, but they are nearly impossible to recycle if they are made from foil-lined…